PROFOUND study
Reference NEJM: Olaparib mCRPC
Germline and somatic BRCA mutation, progressed on hormonal agent like abi or enza
Longer PFS by 3 months in PARP group( 7.4 versus 3.6 months)
Anemia is the most common AE. No AML or MDS reported.
Nausea also common
Key points
- ATM mutations do not respond to PARP inhibitors
- Can use PARP inhibitor even with monoallelic BRCA mutation
- DO not sequence another PARP after failure of one PARP
- Do germline testing in all metastatic prostate cancer patients. Somatic testing is also recommended.
No comments:
Post a Comment